Abstract | AIMS: METHODS: This was a prospective single-arm study including 74 patients (mean age, 64.1 years; male 75.7%) with stroke and hypertriglyceridemia (defined as fasting serum triglycerides levels of ≥ 150 mg/dL) who were treated with pemafibrate at 0.2 mg or 0.1 mg/day. The present report assessed the association of hypertriglyceridemia with cerebral large and small vessel diseases at baseline and changes in laboratory parameters after a three-month pemafibrate therapy. RESULTS: CONCLUSIONS:
|
Authors | Takao Hoshino, Kentaro Ishizuka, Sono Toi, Misa Seki, Kazuo Kitagawa |
Journal | Journal of atherosclerosis and thrombosis
(J Atheroscler Thromb)
Vol. 29
Issue 7
Pg. 1020-1030
(Jul 01 2022)
ISSN: 1880-3873 [Electronic] Japan |
PMID | 34248089
(Publication Type: Journal Article)
|
Chemical References |
- (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid
- Benzoxazoles
- Butyrates
- Triglycerides
|
Topics |
- Atherosclerosis
(complications)
- Benzoxazoles
- Butyrates
- Cerebral Arterial Diseases
(complications)
- Humans
- Hyperlipidemias
(complications)
- Hypertriglyceridemia
(complications, drug therapy)
- Male
- Middle Aged
- Prospective Studies
- Stroke
(drug therapy, prevention & control)
- Triglycerides
|